Corcept Therapeutics Files 8-K
Ticker: CORT · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1088856
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
CORCEPT filed an 8-K, likely routine. Check for details.
AI Summary
On September 10, 2025, Corcept Therapeutics Incorporated filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating a routine update or disclosure rather than a specific material event like an acquisition or major financial change. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Corcept Therapeutics is making a regulatory disclosure, which is standard practice for public companies. Investors should review the full filing for any specific details that may impact the company's operations or financial standing.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain information about significant risks or material adverse events.
Key Players & Entities
- Corcept Therapeutics Incorporated (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 101 Redwood Shores Parkway, Redwood City, CA 94065 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Corcept Therapeutics?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," suggesting a routine disclosure or update.
When was this 8-K report filed?
The report was filed on September 10, 2025.
What is Corcept Therapeutics' state of incorporation?
Corcept Therapeutics Incorporated is incorporated in Delaware.
What is the address of Corcept Therapeutics' principal executive offices?
The principal executive offices are located at 101 Redwood Shores Parkway, Redwood City, CA 94065.
Does this filing indicate any specific material event or financial transaction?
Based on the provided excerpt, the filing is categorized under "Other Events" and "Financial Statements and Exhibits," which does not explicitly detail a specific material event or financial transaction.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-09-10 08:09:04
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
Filing Documents
- d947259d8k.htm (8-K) — 25KB
- d947259dex991.htm (EX-99.1) — 9KB
- g947259g0910085139433.jpg (GRAPHIC) — 5KB
- 0001193125-25-199706.txt ( ) — 152KB
- cort-20250910.xsd (EX-101.SCH) — 3KB
- cort-20250910_lab.xml (EX-101.LAB) — 17KB
- cort-20250910_pre.xml (EX-101.PRE) — 11KB
- d947259d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibits No. Description 99.1 Press Release of Corcept Therapeutics Incorporated, September 10, 2025 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: September 10, 2025 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer